UK's CMA Goes After Advanz, Morningside And Alliance On Nitrofurantoin
The UK’s Competition and Markets Authority has issued a statement of objections to Advanz, Morningside and wholesaler Alliance Healthcare after provisionally finding that the firms broke competition law by arranging to carve up the UK market for nitrofurantoin.
You may also be interested in...
Concordia in clear on three products in UK
Concordia International no longer faces a UK probe into “alleged anti-competitive agreements and/or concerted practices” for three of the firm’s products – trazodone, nefopam and dicycloverine – after the country’s Competition and Markets Authority (CMA) closed an investigation on “administrative priority grounds”.
Concordia Names Six Drugs Targeted By UK Competition Inquiry
Concordia has announced that six more of its medicines are involved in the UK competition inquiry. One law firm says the announcement further underlines the Competition and Markets Authority’s determination to root out anticompetitive practices in the pharma area.
UAE’s Bioventure Is Looking For Partners To Expand
Having recently added to its biosimilars alliance with Alvotech, Dubai-based Bioventure says it is looking to expand its international reach through further partnerships.